In a phase 3 clinical trial, mean cutaneous safety
and tolerability scores (range 0-3) were generally mild at 12 weeks2,3

Severe3

Moderate2

Mild1

Cutaneous Safety Evaluations

Tolerability Evaluations (Patient Reported)

  • Onexton
  • Vehicle
  • At Week 12, no more than 2% of patients studied showed moderate local skin reactions, and fewer than 1% showed severe reactions2
  • Some skin reactions increased during treatment, peaked around Week 4, and returned to baseline or improved by Week 122

MOST COMMON ADVERSE EVENTS (AEs) OCCURRED IN <0.5% OF PATIENTS OVER 12 WEEKS2

  • Contact dermatitis (0.4%)
  • |
  • Pruritus (0.4%)
  • |
  • Burning sensation (0.4%)
  • |
  • Rash (0.4%)